Treatment of Low-Grade B-Cell Primary Pulmonary Lymphoma (MALT Type) with Bilateral or Extrapulmonary Involvement

In low-grade B-cell primary pulmonary lymphoma of MALT type, the clinical approach is shaped by the extent and behaviour of disease. Bilateral pulmonary involvement, extrapulmonary spread, or relapse and progression define a specific presentation that requires a distinct management strategy.

Clinical Scenario

This protocol addresses patients with low-grade B-cell primary pulmonary lymphoma (MALT type) who present with bilateral pulmonary involvement, extrapulmonary disease, or relapse and progression. Exclusive chemotherapy is generally used in this setting.

Treatment Approach — Partial Summary

Exclusive single-agent chemotherapy is the established approach for this presentation — the full protocol, including agent options and the evidence regarding combination regimens, is available in the structured evidence-based regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1183/09031936.02.00404102

Exclusive chemotherapy is generally used for patients with bilateral or extrapulmonary involvement, relapse or progression.

Combination regimens, such as cyclophosphamide, adriamycin, oncovin and prednisone (CHOP), have not proven more effective than single-agent regimens with chloraminophene, cyclophosphamide, azathioprine or steroids.

View source ↗